Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease

P. Klivényi, Robert J. Ferrante, Gabrielle Gardian, Susan Browne, Pierre Etienne Chabrier, M. Flint Beal

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

There is substantial evidence that excitotoxicity and oxidative damage may contribute to Huntington's disease (HD) pathogenesis. We examined whether the novel anti-oxidant compound BN82451 exerts neuroprotective effects in the R6/2 transgenic mouse model of HD. Oral administration of BN82451 significantly improved motor performance and improved survival by 15%. Oral administration of BN82451 significantly reduced gross brain atrophy, neuronal atrophy and the number of neuronal intranuclear inclusions at 90 days of age. These findings provide evidence that novel anti-oxidants such as BN82451 may be useful for treating HD.

Original languageEnglish
Pages (from-to)267-272
Number of pages6
JournalJournal of Neurochemistry
Volume86
Issue number1
DOIs
Publication statusPublished - Jul 2003

Fingerprint

Huntington Disease
Neuroprotective Agents
Transgenic Mice
Oxidants
Atrophy
Oral Administration
Intranuclear Inclusion Bodies
Brain
BN82451

Keywords

  • Experimental therapeutics
  • Huntington
  • Inflammation
  • Neurodegeneration
  • Oxidative damage
  • Transgenic mice

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. / Klivényi, P.; Ferrante, Robert J.; Gardian, Gabrielle; Browne, Susan; Chabrier, Pierre Etienne; Beal, M. Flint.

In: Journal of Neurochemistry, Vol. 86, No. 1, 07.2003, p. 267-272.

Research output: Contribution to journalArticle

Klivényi, P. ; Ferrante, Robert J. ; Gardian, Gabrielle ; Browne, Susan ; Chabrier, Pierre Etienne ; Beal, M. Flint. / Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. In: Journal of Neurochemistry. 2003 ; Vol. 86, No. 1. pp. 267-272.
@article{ef0ea9b0404b4a3a832a00559e651e29,
title = "Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease",
abstract = "There is substantial evidence that excitotoxicity and oxidative damage may contribute to Huntington's disease (HD) pathogenesis. We examined whether the novel anti-oxidant compound BN82451 exerts neuroprotective effects in the R6/2 transgenic mouse model of HD. Oral administration of BN82451 significantly improved motor performance and improved survival by 15{\%}. Oral administration of BN82451 significantly reduced gross brain atrophy, neuronal atrophy and the number of neuronal intranuclear inclusions at 90 days of age. These findings provide evidence that novel anti-oxidants such as BN82451 may be useful for treating HD.",
keywords = "Experimental therapeutics, Huntington, Inflammation, Neurodegeneration, Oxidative damage, Transgenic mice",
author = "P. Kliv{\'e}nyi and Ferrante, {Robert J.} and Gabrielle Gardian and Susan Browne and Chabrier, {Pierre Etienne} and Beal, {M. Flint}",
year = "2003",
month = "7",
doi = "10.1046/j.1471-4159.2003.t01-1-01868.x",
language = "English",
volume = "86",
pages = "267--272",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease

AU - Klivényi, P.

AU - Ferrante, Robert J.

AU - Gardian, Gabrielle

AU - Browne, Susan

AU - Chabrier, Pierre Etienne

AU - Beal, M. Flint

PY - 2003/7

Y1 - 2003/7

N2 - There is substantial evidence that excitotoxicity and oxidative damage may contribute to Huntington's disease (HD) pathogenesis. We examined whether the novel anti-oxidant compound BN82451 exerts neuroprotective effects in the R6/2 transgenic mouse model of HD. Oral administration of BN82451 significantly improved motor performance and improved survival by 15%. Oral administration of BN82451 significantly reduced gross brain atrophy, neuronal atrophy and the number of neuronal intranuclear inclusions at 90 days of age. These findings provide evidence that novel anti-oxidants such as BN82451 may be useful for treating HD.

AB - There is substantial evidence that excitotoxicity and oxidative damage may contribute to Huntington's disease (HD) pathogenesis. We examined whether the novel anti-oxidant compound BN82451 exerts neuroprotective effects in the R6/2 transgenic mouse model of HD. Oral administration of BN82451 significantly improved motor performance and improved survival by 15%. Oral administration of BN82451 significantly reduced gross brain atrophy, neuronal atrophy and the number of neuronal intranuclear inclusions at 90 days of age. These findings provide evidence that novel anti-oxidants such as BN82451 may be useful for treating HD.

KW - Experimental therapeutics

KW - Huntington

KW - Inflammation

KW - Neurodegeneration

KW - Oxidative damage

KW - Transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=0037971143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037971143&partnerID=8YFLogxK

U2 - 10.1046/j.1471-4159.2003.t01-1-01868.x

DO - 10.1046/j.1471-4159.2003.t01-1-01868.x

M3 - Article

VL - 86

SP - 267

EP - 272

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 1

ER -